We have established a diverse portfolio of proprietary product development programs, that includes both pharmaceuticals and biologics. Our pharmaceutical development programs are focused on developing novel treatments for obesity, as well as for attention and cognitive disorders and other indications. In addition, we are developing a patented and proprietary stem cell product, MultiStem, that we believe has potential for treating multiple disease conditions, including in the cardiovascular, oncology, and neurological areas.
Since the summer of 2007, we have advanced several programs into clinical development, across a range of disease areas, including obesity, cancer treatment support, and cardiovascular disease. We believe that our pipeline can be broadened over time, driven by our technologies, capabilities and approach. In particular, we believe that MultiStem has significant therapeutic potential across a range of clinical indications, such as for treating ischemic injury and immune system disorders.
By maintaining a lean infrastructure, and working collaboratively with others, including leading academic researchers, clinical centers, contract research organizations, and contract manufacturing organizations, we are able to efficiently and cost effectively advance multiple programs in parallel.